Olof TydÉn
MD, PhD, Board member
Oncology
Oncopeptides
Sweden
Biography
Olof Tydén was appointed to the board of Oncopeptides in 2014. In addition to his directorship with Oncopeptides, Olof is a Partner at Eureda, an international pharmaceutical consulting firm. Olof has previously held positions as Medical Director at Leo Pharmaceuticals and Kabi-Vitrum (now Pfizer) and Programme Director at the Medical Products Agency in Sweden. Olaf was for six years Senior Regulatory Adviser at Hoffman-La Roche with responsibility for EU strategies, knowledge management and training. In 2000 he founded Eureda, a strategic regulatory consultancy. Olof has also served as an expert to the European Commission in Health Telematics and has been a member of the board of life sciences companies Bioxell SpA, Aprea AB, Cantargia AB and Ximmune AB. Olof holds a PhD from Uppsala University and an associate professorship in obstetrics and gynaecology at Uppsala University. Born: 1947 Holdings in Oncopeptides: 1,000 shares and 49 Share Options* Other current positions: Director of Eureda AB. Alternate Director of Uppsala Medical Information AB.
Research Interest
Independent in relation to the Company, its senior management and major shareholders.
